 Laura Ramsey
Concepts (347)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacogenetics | 32 | 2024 | 170 | 8.100 |
Why?
| | Methotrexate | 10 | 2023 | 27 | 5.020 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 19 | 2023 | 60 | 4.450 |
Why?
| | Humans | 83 | 2024 | 6599 | 3.740 |
Why?
| | Cytochrome P-450 CYP2D6 | 15 | 2024 | 180 | 3.650 |
Why?
| | Antipsychotic Agents | 4 | 2024 | 14 | 3.230 |
Why?
| | Anxiety Disorders | 9 | 2021 | 21 | 3.210 |
Why?
| | Child | 42 | 2024 | 3146 | 2.980 |
Why?
| | Adolescent | 36 | 2024 | 2087 | 2.960 |
Why?
| | Sertraline | 7 | 2023 | 10 | 2.820 |
Why?
| | Depressive Disorder | 5 | 2022 | 11 | 2.640 |
Why?
| | Citalopram | 8 | 2024 | 13 | 2.350 |
Why?
| | Genotype | 21 | 2024 | 395 | 2.320 |
Why?
| | Male | 34 | 2024 | 3197 | 2.110 |
Why?
| | Cytochrome P-450 CYP2C19 | 10 | 2024 | 54 | 2.100 |
Why?
| | Antimetabolites, Antineoplastic | 5 | 2023 | 23 | 2.080 |
Why?
| | Polymorphism, Single Nucleotide | 12 | 2023 | 340 | 2.030 |
Why?
| | Precision Medicine | 9 | 2021 | 42 | 2.020 |
Why?
| | Antineoplastic Agents | 5 | 2021 | 57 | 1.910 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2022 | 22 | 1.790 |
Why?
| | Retrospective Studies | 13 | 2024 | 1251 | 1.750 |
Why?
| | Female | 31 | 2024 | 3436 | 1.740 |
Why?
| | Dexamethasone | 7 | 2019 | 30 | 1.730 |
Why?
| | Phenotype | 8 | 2024 | 233 | 1.730 |
Why?
| | Organic Anion Transporters | 5 | 2014 | 8 | 1.580 |
Why?
| | Antidepressive Agents | 9 | 2024 | 19 | 1.560 |
Why?
| | Alleles | 7 | 2022 | 197 | 1.410 |
Why?
| | gamma-Glutamyl Hydrolase | 2 | 2020 | 2 | 1.400 |
Why?
| | Child, Preschool | 16 | 2024 | 1459 | 1.320 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2019 | 39 | 1.190 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 71 | 1.170 |
Why?
| | Depressive Disorder, Major | 3 | 2023 | 14 | 1.130 |
Why?
| | Practice Patterns, Physicians' | 3 | 2023 | 82 | 1.130 |
Why?
| | Analgesics, Opioid | 2 | 2023 | 44 | 1.100 |
Why?
| | Asparaginase | 8 | 2019 | 15 | 1.070 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 5 | 2024 | 7 | 1.050 |
Why?
| | Nausea | 2 | 2021 | 15 | 1.030 |
Why?
| | Hyperprolactinemia | 1 | 2024 | 1 | 0.980 |
Why?
| | Bipolar Disorder | 2 | 2024 | 4 | 0.980 |
Why?
| | Pediatrics | 2 | 2023 | 170 | 0.960 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 2 | 2021 | 17 | 0.950 |
Why?
| | Mood Disorders | 2 | 2020 | 8 | 0.950 |
Why?
| | Fluoxetine | 2 | 2021 | 6 | 0.940 |
Why?
| | Serotonin and Noradrenaline Reuptake Inhibitors | 2 | 2023 | 4 | 0.940 |
Why?
| | Medicaid | 1 | 2024 | 37 | 0.940 |
Why?
| | Receptor, Serotonin, 5-HT2A | 3 | 2020 | 3 | 0.930 |
Why?
| | Tacrolimus | 1 | 2023 | 10 | 0.930 |
Why?
| | Mice, Knockout | 3 | 2021 | 54 | 0.930 |
Why?
| | Pharmacokinetics | 1 | 2023 | 14 | 0.920 |
Why?
| | Chronic Pain | 1 | 2023 | 28 | 0.890 |
Why?
| | Tetrahydrofolates | 1 | 2022 | 3 | 0.870 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2023 | 92 | 0.870 |
Why?
| | Kidney Transplantation | 1 | 2023 | 114 | 0.870 |
Why?
| | Mice | 16 | 2021 | 290 | 0.860 |
Why?
| | Pharmaceutical Preparations | 3 | 2023 | 36 | 0.850 |
Why?
| | Antiemetics | 1 | 2021 | 4 | 0.840 |
Why?
| | Acute Kidney Injury | 2 | 2022 | 28 | 0.830 |
Why?
| | Adult | 10 | 2023 | 1233 | 0.830 |
Why?
| | Arthritis | 1 | 2021 | 1 | 0.820 |
Why?
| | Antirheumatic Agents | 1 | 2021 | 14 | 0.810 |
Why?
| | Animals | 16 | 2021 | 563 | 0.800 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 18 | 0.800 |
Why?
| | Prescription Drugs | 1 | 2020 | 4 | 0.790 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2021 | 40 | 0.780 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 50 | 0.780 |
Why?
| | Drug Dosage Calculations | 1 | 2020 | 16 | 0.780 |
Why?
| | Psychopharmacology | 1 | 2020 | 1 | 0.770 |
Why?
| | Aripiprazole | 1 | 2020 | 1 | 0.770 |
Why?
| | Child Health Services | 1 | 2020 | 24 | 0.770 |
Why?
| | Piperazines | 2 | 2019 | 3 | 0.770 |
Why?
| | Decision Support Techniques | 1 | 2020 | 9 | 0.760 |
Why?
| | Models, Theoretical | 1 | 2020 | 10 | 0.760 |
Why?
| | Hospitals, Pediatric | 2 | 2020 | 178 | 0.760 |
Why?
| | Anxiety | 2 | 2021 | 45 | 0.740 |
Why?
| | Osteonecrosis | 6 | 2019 | 6 | 0.740 |
Why?
| | Psychotic Disorders | 1 | 2019 | 1 | 0.740 |
Why?
| | Depression | 2 | 2021 | 68 | 0.730 |
Why?
| | Young Adult | 6 | 2023 | 652 | 0.720 |
Why?
| | Neoplasms | 2 | 2022 | 119 | 0.720 |
Why?
| | Receptors, Kainic Acid | 1 | 2019 | 1 | 0.710 |
Why?
| | Genome-Wide Association Study | 6 | 2017 | 181 | 0.690 |
Why?
| | Infant | 10 | 2021 | 1396 | 0.680 |
Why?
| | Weight Gain | 1 | 2018 | 22 | 0.660 |
Why?
| | Program Development | 1 | 2018 | 16 | 0.660 |
Why?
| | Simvastatin | 3 | 2022 | 10 | 0.660 |
Why?
| | Glucocorticoids | 2 | 2017 | 29 | 0.640 |
Why?
| | Treatment Outcome | 9 | 2020 | 624 | 0.620 |
Why?
| | Muscular Diseases | 2 | 2014 | 2 | 0.610 |
Why?
| | Methyltransferases | 2 | 2014 | 9 | 0.610 |
Why?
| | Computational Biology | 1 | 2017 | 40 | 0.610 |
Why?
| | Patient Care Management | 1 | 2017 | 3 | 0.610 |
Why?
| | B-Lymphocytes | 5 | 2017 | 23 | 0.610 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 96 | 0.600 |
Why?
| | Biomedical Research | 1 | 2017 | 20 | 0.590 |
Why?
| | Electronic Health Records | 3 | 2020 | 61 | 0.520 |
Why?
| | Genetic Variation | 3 | 2021 | 161 | 0.480 |
Why?
| | United States | 5 | 2024 | 646 | 0.480 |
Why?
| | Receptors, Antigen, B-Cell | 2 | 2010 | 3 | 0.470 |
Why?
| | Neoplasm Proteins | 2 | 2022 | 29 | 0.470 |
Why?
| | Polymorphism, Genetic | 4 | 2019 | 89 | 0.440 |
Why?
| | Prospective Studies | 5 | 2023 | 508 | 0.430 |
Why?
| | Genome, Human | 1 | 2013 | 82 | 0.430 |
Why?
| | Exons | 1 | 2011 | 32 | 0.420 |
Why?
| | Genetic Testing | 3 | 2021 | 74 | 0.400 |
Why?
| | Cross-Sectional Studies | 2 | 2024 | 317 | 0.390 |
Why?
| | Immunoglobulin kappa-Chains | 1 | 2010 | 1 | 0.390 |
Why?
| | raf Kinases | 1 | 2010 | 1 | 0.390 |
Why?
| | Calcium Signaling | 1 | 2010 | 2 | 0.390 |
Why?
| | Drug Hypersensitivity | 3 | 2015 | 19 | 0.390 |
Why?
| | Follow-Up Studies | 4 | 2019 | 315 | 0.380 |
Why?
| | Genotyping Techniques | 3 | 2021 | 21 | 0.360 |
Why?
| | Recombinant Proteins | 2 | 2020 | 47 | 0.350 |
Why?
| | Drug Prescriptions | 4 | 2021 | 22 | 0.320 |
Why?
| | Risk Factors | 8 | 2019 | 460 | 0.320 |
Why?
| | Haplotypes | 2 | 2022 | 81 | 0.310 |
Why?
| | Gene Frequency | 2 | 2021 | 88 | 0.310 |
Why?
| | Hypertriglyceridemia | 2 | 2019 | 5 | 0.310 |
Why?
| | Infusions, Intravenous | 2 | 2020 | 26 | 0.300 |
Why?
| | STAT5 Transcription Factor | 3 | 2017 | 6 | 0.280 |
Why?
| | Time Factors | 2 | 2018 | 241 | 0.280 |
Why?
| | Prognosis | 4 | 2019 | 209 | 0.280 |
Why?
| | DNA-Binding Proteins | 3 | 2018 | 35 | 0.280 |
Why?
| | Cytochrome P-450 Enzyme System | 3 | 2022 | 88 | 0.270 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2015 | 2 | 0.260 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2017 | 34 | 0.250 |
Why?
| | Paliperidone Palmitate | 1 | 2024 | 2 | 0.250 |
Why?
| | Risperidone | 1 | 2024 | 2 | 0.250 |
Why?
| | Cytochrome P-450 CYP2C19 Inhibitors | 1 | 2023 | 1 | 0.240 |
Why?
| | Drug Labeling | 2 | 2020 | 4 | 0.240 |
Why?
| | Fluconazole | 1 | 2023 | 2 | 0.240 |
Why?
| | Oxycodone | 1 | 2023 | 4 | 0.240 |
Why?
| | Codeine | 1 | 2023 | 15 | 0.230 |
Why?
| | Databases, Factual | 1 | 2024 | 105 | 0.230 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2020 | 16 | 0.230 |
Why?
| | Immunosuppressive Agents | 1 | 2023 | 37 | 0.230 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2023 | 46 | 0.230 |
Why?
| | Education, Distance | 1 | 2022 | 5 | 0.220 |
Why?
| | Medicine | 1 | 2022 | 10 | 0.220 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2022 | 6 | 0.220 |
Why?
| | Inactivation, Metabolic | 2 | 2020 | 15 | 0.220 |
Why?
| | Drug Interactions | 3 | 2020 | 30 | 0.210 |
Why?
| | Ohio | 2 | 2019 | 8 | 0.210 |
Why?
| | Signal Transduction | 5 | 2020 | 107 | 0.210 |
Why?
| | Mice, Inbred C57BL | 4 | 2015 | 76 | 0.210 |
Why?
| | Ondansetron | 1 | 2021 | 3 | 0.210 |
Why?
| | Vomiting | 1 | 2021 | 23 | 0.210 |
Why?
| | Collagen | 1 | 2021 | 3 | 0.210 |
Why?
| | Receptors, Opioid, mu | 1 | 2021 | 4 | 0.200 |
Why?
| | Severity of Illness Index | 2 | 2019 | 142 | 0.200 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 13 | 0.200 |
Why?
| | Sleep Wake Disorders | 1 | 2021 | 18 | 0.200 |
Why?
| | Genetic Predisposition to Disease | 3 | 2017 | 215 | 0.200 |
Why?
| | Anti-Anxiety Agents | 1 | 2020 | 5 | 0.190 |
Why?
| | Psychotropic Drugs | 1 | 2020 | 2 | 0.190 |
Why?
| | Hydrolysis | 1 | 2020 | 3 | 0.190 |
Why?
| | Transcription Factors | 2 | 2018 | 46 | 0.190 |
Why?
| | Clinical Decision-Making | 1 | 2020 | 20 | 0.190 |
Why?
| | Drug Compounding | 1 | 2019 | 1 | 0.180 |
Why?
| | Mental Disorders | 1 | 2020 | 15 | 0.180 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2017 | 33 | 0.180 |
Why?
| | Thyroid Diseases | 1 | 2019 | 1 | 0.180 |
Why?
| | Thyrotropin | 1 | 2019 | 3 | 0.180 |
Why?
| | Membrane Proteins | 2 | 2017 | 50 | 0.180 |
Why?
| | Dasatinib | 1 | 2019 | 2 | 0.170 |
Why?
| | Tissue Distribution | 1 | 2019 | 10 | 0.170 |
Why?
| | Natural Language Processing | 1 | 2018 | 3 | 0.170 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 2 | 0.170 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2015 | 7 | 0.170 |
Why?
| | Disease Models, Animal | 2 | 2016 | 55 | 0.170 |
Why?
| | Neoplasm Transplantation | 2 | 2015 | 5 | 0.170 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2018 | 4 | 0.160 |
Why?
| | HLA-DRB1 Chains | 2 | 2015 | 5 | 0.160 |
Why?
| | Receptor, PAR-2 | 1 | 2017 | 1 | 0.160 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2017 | 6 | 0.160 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 15 | 0.160 |
Why?
| | Consensus | 1 | 2017 | 31 | 0.160 |
Why?
| | Dyslipidemias | 1 | 2017 | 14 | 0.150 |
Why?
| | Lipase | 1 | 2017 | 2 | 0.150 |
Why?
| | Pre-B Cell Receptors | 1 | 2017 | 1 | 0.150 |
Why?
| | Ikaros Transcription Factor | 1 | 2017 | 3 | 0.150 |
Why?
| | Alanine Transaminase | 1 | 2017 | 5 | 0.150 |
Why?
| | Systems Integration | 1 | 2017 | 6 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2015 | 27 | 0.150 |
Why?
| | Double-Blind Method | 3 | 2021 | 48 | 0.150 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 51 | 0.150 |
Why?
| | Biomarkers, Tumor | 1 | 2017 | 61 | 0.140 |
Why?
| | Trans-Activators | 2 | 2017 | 11 | 0.140 |
Why?
| | Corticosterone | 1 | 2015 | 1 | 0.140 |
Why?
| | Gene Expression Regulation, Leukemic | 2 | 2015 | 9 | 0.140 |
Why?
| | Disease-Free Survival | 1 | 2015 | 45 | 0.130 |
Why?
| | NFATC Transcription Factors | 1 | 2015 | 1 | 0.130 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 40 | 0.130 |
Why?
| | Caspase 1 | 1 | 2015 | 1 | 0.130 |
Why?
| | Receptors, Glucocorticoid | 1 | 2015 | 5 | 0.130 |
Why?
| | Mutation | 2 | 2018 | 194 | 0.130 |
Why?
| | Carrier Proteins | 1 | 2015 | 32 | 0.130 |
Why?
| | Premedication | 1 | 2015 | 2 | 0.130 |
Why?
| | Antibodies | 1 | 2014 | 15 | 0.130 |
Why?
| | Germ Cells | 1 | 2014 | 5 | 0.120 |
Why?
| | Leukemia | 1 | 2014 | 17 | 0.120 |
Why?
| | bcl-X Protein | 1 | 2013 | 2 | 0.120 |
Why?
| | Janus Kinase 2 | 1 | 2013 | 8 | 0.120 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 3 | 0.120 |
Why?
| | Serotonin | 2 | 2023 | 4 | 0.120 |
Why?
| | Homeodomain Proteins | 2 | 2012 | 18 | 0.120 |
Why?
| | Leucovorin | 1 | 2012 | 2 | 0.110 |
Why?
| | Linear Models | 1 | 2012 | 55 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2012 | 74 | 0.110 |
Why?
| | Recurrence | 1 | 2013 | 115 | 0.110 |
Why?
| | Gastrointestinal Tract | 1 | 2012 | 7 | 0.110 |
Why?
| | B-Lymphocyte Subsets | 1 | 2012 | 1 | 0.110 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2012 | 1 | 0.110 |
Why?
| | Interleukin-7 | 1 | 2012 | 2 | 0.110 |
Why?
| | Cell Cycle | 1 | 2012 | 14 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 44 | 0.100 |
Why?
| | Organic Cation Transport Proteins | 1 | 2011 | 1 | 0.100 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2011 | 4 | 0.100 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2012 | 45 | 0.100 |
Why?
| | Cohort Studies | 1 | 2011 | 264 | 0.100 |
Why?
| | Cell Line, Tumor | 3 | 2018 | 87 | 0.100 |
Why?
| | Mice, Inbred BALB C | 3 | 2016 | 25 | 0.100 |
Why?
| | Adolescent Psychiatry | 2 | 2021 | 3 | 0.090 |
Why?
| | Risk Assessment | 3 | 2017 | 130 | 0.090 |
Why?
| | Recombination, Genetic | 1 | 2009 | 3 | 0.090 |
Why?
| | Immunoglobulins | 1 | 2009 | 5 | 0.090 |
Why?
| | Cell Cycle Proteins | 1 | 2009 | 15 | 0.090 |
Why?
| | Tumor Suppressor Proteins | 1 | 2009 | 14 | 0.090 |
Why?
| | Mice, Transgenic | 3 | 2018 | 33 | 0.090 |
Why?
| | Immunoglobulin Light Chains | 1 | 2008 | 2 | 0.080 |
Why?
| | Antigens | 1 | 2008 | 3 | 0.080 |
Why?
| | Genomics | 2 | 2022 | 86 | 0.080 |
Why?
| | Remission Induction | 2 | 2017 | 25 | 0.070 |
Why?
| | Proto-Oncogene Proteins | 2 | 2017 | 17 | 0.070 |
Why?
| | Flow Cytometry | 2 | 2017 | 26 | 0.070 |
Why?
| | Psychomotor Agitation | 1 | 2024 | 1 | 0.060 |
Why?
| | Transcription, Genetic | 2 | 2015 | 44 | 0.060 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2023 | 10 | 0.060 |
Why?
| | Norepinephrine | 1 | 2023 | 12 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 62 | 0.050 |
Why?
| | Health Personnel | 1 | 2022 | 28 | 0.050 |
Why?
| | Seizures | 1 | 2022 | 23 | 0.050 |
Why?
| | Rosuvastatin Calcium | 1 | 2022 | 5 | 0.050 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2022 | 25 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2021 | 43 | 0.050 |
Why?
| | Research | 1 | 2021 | 11 | 0.050 |
Why?
| | Electronic Prescribing | 1 | 2021 | 1 | 0.050 |
Why?
| | Amygdala | 1 | 2021 | 3 | 0.050 |
Why?
| | Reimbursement Mechanisms | 1 | 2020 | 2 | 0.050 |
Why?
| | Area Under Curve | 1 | 2020 | 34 | 0.050 |
Why?
| | Patient Care | 1 | 2020 | 6 | 0.050 |
Why?
| | VDJ Recombinases | 2 | 2011 | 2 | 0.050 |
Why?
| | Software | 1 | 2020 | 24 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2012 | 41 | 0.050 |
Why?
| | Delivery of Health Care | 1 | 2020 | 29 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2021 | 114 | 0.050 |
Why?
| | Marketing of Health Services | 1 | 2019 | 3 | 0.050 |
Why?
| | Aged | 1 | 2021 | 375 | 0.050 |
Why?
| | Ecological Parameter Monitoring | 1 | 2019 | 1 | 0.040 |
Why?
| | Sequence Analysis | 1 | 2019 | 3 | 0.040 |
Why?
| | Heterografts | 1 | 2019 | 3 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2019 | 9 | 0.040 |
Why?
| | Sex Factors | 1 | 2019 | 71 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2019 | 34 | 0.040 |
Why?
| | Prevalence | 1 | 2019 | 145 | 0.040 |
Why?
| | Middle Aged | 1 | 2021 | 648 | 0.040 |
Why?
| | Mutagenesis, Insertional | 1 | 2018 | 1 | 0.040 |
Why?
| | Decision Support Systems, Clinical | 1 | 2019 | 18 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2018 | 5 | 0.040 |
Why?
| | Age Factors | 1 | 2019 | 203 | 0.040 |
Why?
| | Quality Improvement | 1 | 2019 | 60 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2009 | 73 | 0.040 |
Why?
| | Child Psychiatry | 1 | 2018 | 2 | 0.040 |
Why?
| | Catechol O-Methyltransferase | 1 | 2018 | 5 | 0.040 |
Why?
| | Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2018 | 11 | 0.040 |
Why?
| | Protein Kinase C beta | 1 | 2017 | 1 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2017 | 5 | 0.040 |
Why?
| | Interferon Regulatory Factors | 1 | 2017 | 4 | 0.040 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2017 | 2 | 0.040 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2017 | 8 | 0.040 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2017 | 9 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2017 | 31 | 0.040 |
Why?
| | Survival Rate | 1 | 2017 | 84 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2017 | 38 | 0.040 |
Why?
| | Drug Synergism | 1 | 2016 | 7 | 0.040 |
Why?
| | Bone Morphogenetic Protein 7 | 1 | 2015 | 1 | 0.030 |
Why?
| | Escherichia coli | 1 | 2016 | 27 | 0.030 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 2 | 0.030 |
Why?
| | Enzyme Replacement Therapy | 1 | 2015 | 4 | 0.030 |
Why?
| | Inflammasomes | 1 | 2015 | 2 | 0.030 |
Why?
| | Proteolysis | 1 | 2015 | 3 | 0.030 |
Why?
| | Prednisolone | 1 | 2015 | 4 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2015 | 24 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2015 | 30 | 0.030 |
Why?
| | Up-Regulation | 1 | 2015 | 25 | 0.030 |
Why?
| | Base Sequence | 1 | 2015 | 76 | 0.030 |
Why?
| | Fasting | 1 | 2014 | 4 | 0.030 |
Why?
| | Lipids | 1 | 2014 | 7 | 0.030 |
Why?
| | Pancreatitis | 1 | 2014 | 8 | 0.030 |
Why?
| | Thromboembolism | 1 | 2014 | 3 | 0.030 |
Why?
| | Polyethylene Glycols | 1 | 2014 | 12 | 0.030 |
Why?
| | Epitopes | 1 | 2014 | 19 | 0.030 |
Why?
| | DNA Methylation | 1 | 2015 | 108 | 0.030 |
Why?
| | Biphenyl Compounds | 1 | 2013 | 1 | 0.030 |
Why?
| | Nitrophenols | 1 | 2013 | 2 | 0.030 |
Why?
| | Nitriles | 1 | 2013 | 3 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2013 | 6 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2013 | 7 | 0.030 |
Why?
| | Pyrazoles | 1 | 2013 | 3 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2013 | 6 | 0.030 |
Why?
| | Mice, SCID | 1 | 2013 | 12 | 0.030 |
Why?
| | Pyrimidines | 1 | 2013 | 6 | 0.030 |
Why?
| | Cell Survival | 1 | 2013 | 19 | 0.030 |
Why?
| | Sulfonamides | 1 | 2013 | 10 | 0.030 |
Why?
| | Apoptosis | 1 | 2013 | 43 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2013 | 109 | 0.030 |
Why?
| | Species Specificity | 1 | 2012 | 6 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2012 | 24 | 0.030 |
Why?
| | Survival Analysis | 1 | 2012 | 46 | 0.030 |
Why?
| | Body Weight | 1 | 2012 | 49 | 0.030 |
Why?
| | HapMap Project | 1 | 2012 | 3 | 0.030 |
Why?
| | Genes | 1 | 2012 | 9 | 0.030 |
Why?
| | Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2012 | 1 | 0.030 |
Why?
| | Genes, RAG-1 | 1 | 2012 | 1 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2012 | 3 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2012 | 4 | 0.030 |
Why?
| | Gene Expression | 1 | 2012 | 60 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 64 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2015 | 790 | 0.030 |
Why?
| | Receptors, Interleukin-7 | 1 | 2011 | 2 | 0.030 |
Why?
| | Heterozygote | 1 | 2011 | 23 | 0.030 |
Why?
| | Conserved Sequence | 1 | 2011 | 5 | 0.030 |
Why?
| | Biological Transport | 1 | 2011 | 16 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2011 | 55 | 0.020 |
Why?
| | Binding Sites | 1 | 2011 | 26 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2011 | 107 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 98 | 0.020 |
Why?
| | Liver | 1 | 2011 | 119 | 0.020 |
Why?
| | DNA Breaks | 1 | 2009 | 2 | 0.020 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2009 | 2 | 0.020 |
Why?
| | Gene Rearrangement | 1 | 2009 | 8 | 0.020 |
Why?
| | Phorbol Esters | 1 | 2008 | 1 | 0.020 |
Why?
| | Receptors, Fc | 1 | 2008 | 1 | 0.020 |
Why?
| | src-Family Kinases | 1 | 2008 | 1 | 0.020 |
Why?
| | Ionophores | 1 | 2008 | 3 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2008 | 11 | 0.020 |
Why?
| | Down-Regulation | 1 | 2008 | 14 | 0.020 |
Why?
| | Kinetics | 1 | 2008 | 30 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|